Formycon AG Reports Non-Cash Impairments and Revises EBITDA Guidance

Formycon AG has announced non-cash impairments for its biosimilars FYB201 and FYB202. These impairments stem from reduced revenue expectations by commercialization partners, impacting the company's financial outlook. Consequently, Formycon has adjusted its EBITDA guidance for 2026, now expecting a range of -15 million EUR to -5 million EUR. This contrasts with the previous forecast of 5 million EUR to 15 million EUR.

The impairments, recorded during a regular quarterly evaluation, will reduce the company’s net income by 82 million EUR for FYB202 and 39 million EUR for FYB201, though these are non-cash losses. Revenue projections remain between 60 million EUR and 70 million EUR, with net working capital at the year's end anticipated to be 20 million EUR to 30 million EUR.

Formycon assures that other development projects remain unaffected. Further details will be presented on November 12, 2026, during a scheduled conference call.